Repare Therapeutics Inc (RPTX) gains 0.83% for July 21

Equities Staff  |

Repare Therapeutics Inc (NASDAQ: RPTX) shares gained 0.83%, or $0.28 per share, to close Wednesday at $34.20. After opening the day at $34.10, shares of Repare fluctuated between $34.59 and $33.01. 80,595 shares traded hands a decrease from their 30 day average of 170,706. Wednesday's activity brought Repare’s market cap to $1,265,424,179.

About Repare Therapeutics Inc

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Pol? inhibitor program.

Visit Repare Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Repare Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Repare Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content